| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2005.01.6071 |
| P698 | PubMed publication ID | 16260700 |
| P50 | author | Marc Buyse | Q38291268 |
| Jean Francois Seitz | Q38295559 | ||
| Roberto Labianca | Q39950156 | ||
| Daniel J. Sargent | Q43055483 | ||
| Richard Gray | Q56436574 | ||
| P2093 | author name string | Richard M Goldberg | |
| David Kerr | |||
| Axel Grothey | |||
| Aimery De Gramont | |||
| Charles D Blanke | |||
| Christopher J O'Callaghan | |||
| Daniel G Haller | |||
| Erin Green | |||
| Guido Francini | |||
| Harry S Wieand | |||
| Jacqueline K Benedetti | |||
| Michael O'Connell | |||
| Norman Wolmark | |||
| Paul J Catalano | |||
| Thierry Andre | |||
| P433 | issue | 34 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| colon cancer | Q18555025 | ||
| P304 | page(s) | 8664-8670 | |
| P577 | publication date | 2005-10-31 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials | |
| P478 | volume | 23 |
| Q92887519 | 1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours |
| Q38691539 | A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses |
| Q38538562 | A Quantitative Process for Enhancing End of Phase 2 Decisions |
| Q99609257 | A persistent high neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with colorectal cancer undergoing resection |
| Q36759996 | A randomized phase II dose-response exercise trial among colon cancer survivors: Purpose, study design, methods, and recruitment results. |
| Q45945682 | A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. |
| Q38272671 | A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer |
| Q37966610 | A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer |
| Q36411980 | A systematic review of patient perspectives on surveillance after colorectal cancer treatment |
| Q30301332 | ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer |
| Q47718910 | Addition of platinum derivatives to neoadjuvant single-agent fluoropyrimidine chemoradiotherapy in patients with stage II/III rectal cancer: protocol for a systematic review and meta-analysis (PROSPERO CRD42017073064). |
| Q33396630 | Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer |
| Q99414143 | Adjuvant Chemotherapy for Stage II Colon Cancer |
| Q37167151 | Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough? |
| Q96811980 | Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma |
| Q24242231 | Adjuvant Therapy for completely resected Stage II Colon Cancer |
| Q86826431 | Adjuvant and neoadjuvant therapy for gastric cancer |
| Q30625567 | Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. |
| Q37481599 | Adjuvant chemotherapy in carcinoma colon: Is there a rationale to change practice for Asian patients? |
| Q61868117 | Adjuvant chemotherapy of colorectal cancer |
| Q34725978 | Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. |
| Q37956401 | Adjuvant therapy for early colon cancer: current status |
| Q37427518 | Adjuvant therapy of colon cancer: current status and future developments |
| Q46866916 | Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience |
| Q83603989 | Adjuvant treatment of colorectal cancer |
| Q85106724 | An information-theoretic approach to surrogate-marker evaluation with failure time endpoints |
| Q37082491 | Angiogenesis as a strategic target for ovarian cancer therapy |
| Q45144314 | Assessing Cancer Drugs for Reimbursement: Methodology, Relationship between Effect Size and Medical Need |
| Q33518321 | Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set |
| Q97531398 | Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review |
| Q49871641 | Association of rs2282679 A>C polymorphism in vitamin D binding protein gene with colorectal cancer risk and survival: effect modification by dietary vitamin D intake |
| Q39213203 | BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis |
| Q39166273 | Bayesian adaptive trial design for a newly validated surrogate endpoint |
| Q51476184 | Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials. |
| Q38084158 | Benefit and harms of new anti-cancer drugs |
| Q34276740 | Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set |
| Q39628955 | Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research |
| Q37821843 | Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: the role of anti-VEGF and anti-EGFR antibodies |
| Q37724573 | Biomarkers and surrogate end points--the challenge of statistical validation |
| Q37477466 | Biotherapy in the Adjuvant Treatment of Colorectal Cancer |
| Q44939902 | Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study |
| Q35044261 | Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials |
| Q30370596 | Center-Within-Trial Versus Trial-Level Evaluation of Surrogate Endpoints |
| Q44997588 | Chances and limitations of chemotherapy in elderly patients |
| Q43253763 | Chemotherapy: Adding oxaliplatin to the equation |
| Q35584698 | Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer |
| Q99545825 | Clinical trial design: Past, present, and future in the context of big data and precision medicine |
| Q34473636 | Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. |
| Q37709717 | Colorectal Cancer OncoGuia |
| Q55924124 | Colorectal cancer |
| Q36913615 | Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy |
| Q36475875 | Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications |
| Q34567058 | Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study |
| Q38291492 | Computed tomography perfusion imaging as a potential imaging biomarker of colorectal cancer |
| Q33897641 | Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. |
| Q33434559 | Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer |
| Q53094239 | Correlation of TNFAIP8 overexpression with the proliferation, metastasis, and disease-free survival in endometrial cancer. |
| Q40249789 | Cost-Effectiveness Analysis of Adjuvant Stage III Colon Cancer Treatment at Veterans Affairs Medical Centers |
| Q36611904 | Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer |
| Q33680331 | Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada |
| Q38040419 | Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients. |
| Q37077225 | Current status of adjuvant therapy for colon cancer. |
| Q46889935 | Death of a clinical trial: a speculative inclusion criterion gone wrong |
| Q35917852 | Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database |
| Q35205035 | Development of a claims-based algorithm to identify colorectal cancer recurrence. |
| Q36221402 | Disease-Free Survival at 2 and 3 Years is a Significant Early Surrogate Marker Predicting the 5-Year Overall Survival in Patients Treated with Radical Cystectomy for Urothelial Carcinoma of the Bladder: External Evaluation and Validation in a Cohort |
| Q26860637 | Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis |
| Q91310992 | Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis |
| Q84046246 | Does a laparoscopic approach affect the number of lymph nodes harvested during curative surgery for colorectal cancer? |
| Q80198225 | Don't forget survival, please... |
| Q49960264 | Dose-response effects of aerobic exercise on body composition among colon cancer survivors: a randomised controlled trial |
| Q88202109 | Duration of Adjuvant Chemotherapy for Stage III Colon Cancer |
| Q34381843 | EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis |
| Q36934350 | Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study |
| Q38175833 | Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies |
| Q104060413 | Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials |
| Q37309453 | Effects of tyrosine kinase inhibitor E7080 and eNOS inhibitor L-NIO on colorectal cancer alone and in combination |
| Q50333599 | Emergency resection surgery for colorectal cancer: Patterns of recurrent disease and survival |
| Q37952239 | End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era. |
| Q36862977 | Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials |
| Q33557040 | Endpoints in phase II trials for advanced non-small cell lung cancer |
| Q37441277 | Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohorts |
| Q37901096 | Estimating changes in overall survival using progression-free survival in metastatic breast and colorectal cancer |
| Q35672166 | Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes |
| Q47912286 | Evaluation of early efficacy endpoints for proof-of-concept trials |
| Q33397671 | Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials |
| Q35815161 | Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan |
| Q59901612 | Exploring and validating surrogate endpoints in colorectal cancer |
| Q34863307 | Extracapsular invasion as a risk factor for disease recurrence in colorectal cancer. |
| Q34597274 | FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer |
| Q92523414 | FOXE1 represses cell proliferation and Warburg effect by inhibiting HK2 in colorectal cancer |
| Q47168599 | Factors associated with short recurrence-free survival in completely resected colon cancer |
| Q81153980 | Factors influencing lymph node harvest in colorectal surgery |
| Q82660561 | Failure of bevacizumab in early-stage colon cancer |
| Q47430316 | Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials |
| Q98891380 | GLUT3 induced by AMPK/CREB1 axis is key for withstanding energy stress and augments the efficacy of current colorectal cancer therapies |
| Q33773546 | Genetic variations affecting serum carcinoembryonic antigen levels and status of regional lymph nodes in patients with sporadic colorectal cancer from Southern China |
| Q47877600 | Geriatric Assessment Predicts Survival and Competing Mortality in Elderly Patients with Early Colorectal Cancer: Can It Help in Adjuvant Therapy Decision-Making? |
| Q89020079 | Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance) |
| Q51943250 | Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy). |
| Q40918277 | HER3 expression is correlated to distally located and low-grade colon cancer |
| Q47124210 | Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials. |
| Q51199086 | Health benefits and costs of screening for colorectal cancer in people on dialysis or who have received a kidney transplant. |
| Q38557683 | Health status and needs of cancer survivors attending the Sydney Survivorship Centre clinics and programmes: a protocol for longitudinal evaluation of the centre's services |
| Q40847140 | High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer. |
| Q35004750 | Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points |
| Q35602966 | Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised tri |
| Q41865845 | Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points |
| Q30315675 | Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. |
| Q41587108 | Improving efficiency in clinical trials using auxiliary information: Application of a multi-state cure model |
| Q41735144 | Increasing utilization and predictors of hematopoietic growth factors in patients diagnosed with colorectal cancer: findings from a large national population-based cohort in the USA, 1992-2009. |
| Q40122418 | Individual- and trial-level surrogacy in colorectal cancer |
| Q36663632 | Innovative estimation of survival using log-normal survival modelling on ACCENT database. |
| Q40122830 | Interim futility analysis with intermediate endpoints |
| Q38261859 | Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials |
| Q40489826 | Intra-tumoural stromal morphometry predicts disease recurrence but not response to 5-fluorouracil - results from the QUASAR trial of colorectal cancer. |
| Q27025943 | Is blood pressure reduction a valid surrogate endpoint for stroke prevention? [etc.] |
| Q37671970 | Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer? |
| Q37231532 | Issues in using progression-free survival when evaluating oncology products |
| Q33693309 | KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). |
| Q53277669 | KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. |
| Q84879102 | Laparoscopic colectomy for colonic carcinoma |
| Q37734291 | Laparoscopic surgery for rectal cancer: short-term benefits and oncologic outcomes using more than one technique |
| Q42852367 | Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. |
| Q36524276 | Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor |
| Q37328344 | Low-Level Microsatellite Instability as a Potential Prognostic Factor in Sporadic Colorectal Cancer |
| Q38476236 | Lymph node ratio as determined by the 7th edition of the American Joint Committee on Cancer staging system predicts survival in stage III colon cancer |
| Q34364879 | Markers for nutrition studies: review of criteria for the evaluation of markers |
| Q43787549 | Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling |
| Q37458317 | Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. |
| Q37955095 | Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer |
| Q38630553 | Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer |
| Q45141920 | Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer |
| Q35530394 | Mining the ACCENT database: a review and update |
| Q46352194 | Molecular targets for colon cancer. VEGF, EGFR - and what else? |
| Q35930778 | Multi Texture Analysis of Colorectal Cancer Continuum Using Multispectral Imagery |
| Q21142734 | Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer |
| Q37723667 | Multi-state models for colon cancer recurrence and death with a cured fraction |
| Q35825822 | Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer |
| Q37301707 | North Central Cancer Treatment Group--achievements and perspectives |
| Q37362990 | On assessing surrogacy in a single trial setting using a semicompeting risks paradigm |
| Q35222351 | Overall survival after resection for colon cancer in a national cohort study was adversely affected by TNM stage, lymph node ratio, gender, and old age. |
| Q37242664 | Oxaliplatin-based chemotherapy in the management of colorectal cancer |
| Q26992267 | PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis |
| Q37612390 | PIK3CA in Colorectal Cancer |
| Q27852105 | PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis |
| Q38246587 | PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials |
| Q36525431 | Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint |
| Q34974202 | Pathways, outcomes, and costs in colon cancer: retrospective evaluations in two distinct databases |
| Q38101747 | Pitfalls in outcome prediction of breast cancer. |
| Q43596622 | Polymorphisms in genes of APE1, PARP1, and XRCC1: risk and prognosis of colorectal cancer in a northeast Chinese population |
| Q36095249 | Population-based longitudinal study of follow-up care for patients with colorectal cancer in Nova Scotia |
| Q40461237 | Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. |
| Q94551692 | Postoperative Fasting Blood Glucose Predicts Prognosis in Stage I-III Colorectal Cancer Patients Undergoing Resection |
| Q37324245 | Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial |
| Q35556037 | Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time |
| Q36573082 | Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience |
| Q92141995 | Prognostic Value of Radiologic Extranodal Extension in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma |
| Q34982575 | Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy |
| Q36896188 | Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy |
| Q35807716 | Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients |
| Q80504721 | Prognostic models for predicting death after hepatectomy in individuals with hepatic metastases from colorectal cancer |
| Q47580220 | Prognostic significance of neoadjuvant rectal score in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and construction of a prediction model. |
| Q44713711 | Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study |
| Q41421740 | Prognostic value of routine laboratory variables in prediction of breast cancer recurrence |
| Q37134442 | Progress and challenges in the adjuvant treatment of stage II and III colon cancers |
| Q57164614 | Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL) |
| Q33927755 | Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. |
| Q36552307 | Progression-free survival as a surrogate endpoint in advanced breast cancer |
| Q34656803 | Progression-free survival as endpoint in metastatic RCC? |
| Q37630084 | Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature |
| Q39933767 | Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer |
| Q86966561 | Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? |
| Q36688005 | Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting analysis dates for the IDEA collaboration |
| Q38089641 | Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis |
| Q99578634 | Radiomics of rectal cancer for predicting distant metastasis and overall survival |
| Q35009893 | Raltitrexed: optimism and reality |
| Q36822186 | Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer |
| Q37206159 | Recent advances in the molecular diagnosis and prognosis of colorectal cancer |
| Q36627254 | Recent developments in colorectal cancer treatment by monoclonal antibodies |
| Q37034524 | Rectal cancer staging: focus on the prognostic significance of the findings described by high-resolution magnetic resonance imaging |
| Q36977501 | Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer |
| Q56588945 | Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis |
| Q36349459 | Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology |
| Q50596655 | Robot-assisted laparoscopic versus open pancreaticoduodenectomy: a prospective, matched, mid-term follow-up study. |
| Q33346616 | Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost-effectiveness and serious clinical events |
| Q34132767 | Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide |
| Q36761405 | Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers |
| Q91843007 | Splenomegaly in Colon Cancer During Adjuvant Oxaliplatin-based Chemotherapy |
| Q28088693 | Standard chemotherapy with cetuximab for treatment of colorectal cancer |
| Q36658054 | Statistical aspect of translational and correlative studies in clinical trials |
| Q37676061 | Statistical assessment of biosimilar products |
| Q38093778 | Statistical challenges in the evaluation of treatments for small patient populations |
| Q38356102 | Statistical evaluation of surrogate endpoints with examples from cancer clinical trials |
| Q90130287 | Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling |
| Q90288455 | Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q36215439 | Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis |
| Q36727471 | Surrogate endpoint analysis: an exercise in extrapolation |
| Q47098597 | Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients' data |
| Q50645658 | Surrogate endpoint validation: statistical elegance versus clinical relevance. |
| Q30627447 | Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data |
| Q33600372 | Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists |
| Q46745109 | Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective |
| Q33412969 | Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data |
| Q64999466 | Surrogate endpoints in head and neck cancer. |
| Q54542682 | Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials. |
| Q33921813 | Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? |
| Q38829245 | Surrogate marker analysis in cancer clinical trials through time-to-event mediation techniques |
| Q37402280 | Surrogate markers of overall survival in metastatic colorectal cancer: an evolving challenge still more complex with repeat surgery |
| Q38668745 | Survival analysis in rectal carcinoma after neoadjuvant chemoradiation: various methods with different results |
| Q34046556 | Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival |
| Q35511840 | Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†. |
| Q36905273 | Symptomatic and Asymptomatic Colon Cancer Recurrence: A Multicenter Cohort Study |
| Q28084403 | Systematic Review: Adjuvant Chemotherapy for Locally Advanced Rectal Cancer with respect to Stage of Disease |
| Q39295492 | TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials |
| Q42953392 | Temsirolimus: Is Improved Survival the Correct Expression of Drug Activity? |
| Q53728886 | Texture Analysis of Abnormal Cell Images for Predicting the Continuum of Colorectal Cancer. |
| Q90316031 | The ColoCare Study: A Paradigm of Transdisciplinary Science in Colorectal Cancer Outcomes |
| Q37011670 | The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group |
| Q38593365 | The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). |
| Q38629758 | The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project |
| Q89379961 | The big, the bad, and the exon 11: adjuvant imatinib for all gastro-intestinal stromal tumors or just the ugly? |
| Q36253811 | The effect of laparoscopic surgery in stage II and III right-sided colon cancer: a retrospective study |
| Q64074016 | The impact of provider payment reforms and associated care delivery models on cost and quality in cancer care: A systematic literature review |
| Q33898741 | The influence of micrometastases on prognosis and survival in stage I-II colon cancer patients: the Enroute⊕ Study |
| Q41513151 | The prognostic significance of serum and cerebrospinal fluid MMP-9, CCL2 and sVCAM-1 in leukemia CNS metastasis |
| Q35688316 | The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme |
| Q80799551 | Time to first flare-up episode of GVHD can stratify patients according to their prognosis during clinical course of progressive- or quiescent-type chronic GVHD |
| Q36029900 | Tissue microRNA-21 expression predicted recurrence and poor survival in patients with colorectal cancer - a meta-analysis |
| Q37118543 | Translating cancer trial endpoints into the language of managed care |
| Q34476583 | Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma |
| Q34512144 | Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials |
| Q35584926 | Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741 |
| Q33800611 | Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C |
| Q33320407 | Two simple approaches for validating a binary surrogate endpoint using data from multiple trials |
| Q50710717 | Unmet needs in the first-line treatment of follicular lymphoma. |
| Q47817649 | Unnecessary surgery can be avoided by judicious use of PET/CT scanning in colorectal cancer patients |
| Q35654260 | Upregulated Polo-Like Kinase 1 Expression Correlates with Inferior Survival Outcomes in Rectal Cancer |
| Q55114129 | Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study. |
| Q35403636 | Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival. |
| Q38758684 | Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials |
| Q33394106 | Validation of novel imaging methodologies for use as cancer clinical trial end-points |
| Q37507061 | Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database |
| Q42642029 | Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525. |
| Q47285151 | Young Vs Old Colorectal Cancer in Indian Subcontinent: a Tertiary Care Center Experience |
| Q79630746 | [The impact of minimally invasive techniques in colorectal surgery] |
Search more.